About Cipher Pharmaceuticals Inc.
Message Board..
http://www.stockhouse.com/companies/bullboards/t.dnd/cipher-pharmaceuticals-inc.
News Releases..
http://micro.newswire.ca/55305-0.html
Cipher Pharmaceuticals (TSX: DND) (OTC: CPHMF) is a growing specialty pharmaceutical company that commercializes novel formulations of successful, currently marketed molecules. Cipher's strategy is to in-license clearly differentiated products, advance them through the clinical development and regulatory approval stages, and out-license to international marketing partners. For more information, please visit www.cipherpharma.com.
Cipher's first product is a fenofibrate formulation marketed in the United States as Lipofen®. Cipher's second product, an extended-release tramadol, is marketed in the United States as ConZip® and in Canada as Durela®. Cipher's third product, a novel formulation of the acne treatment isotretinoin, was approved by the FDA in May and was launched in the United States in Q4 2012 as Absorica™. The product was also recently approved by Health Canada and Cipher expects to launch it as Epuris™ in Canada in early Q3 2013.
Mississauga-based Cipher Pharmaceuticals is a spinoff of CML Healthcare, a more than three-decades old medical imaging company that shed its drug development division, which was burning cash, when it decided to convert to an income trust. The resulting spinoff, Cipher, transitioned from being defined by its relative risk to being notable for its comparative safety. Unlike many of its newfound peers, Cipher has carved out a sweet spot in the middle of the drug development process, identifying late stage product candidates with near term market potential.
Last year was a good one for Cipher Pharma, especially after May when the company announced it had received FDA approval for acne treatment Absorica. Absorica was the third Cipher product to receive regulatory approval. Since 2007, the company has derived most of its revenue from cholesterol treatment drug Lipofen, and in Q3 of last year it began to market ConZip, a Tramadol treatment for moderate to moderately severe chronic pain.
Cipher management, however, believes Absorica could be the first Cipher product to be truly differentiated from its competition.
While Lipofen and Conzip have found niche markets, the products were not first to market and competed in relatively crowded spaces. Loe points out that in the first two months alone, Absorica achieved 3.6% prescription market share against lower-priced generic alternatives.
Absorica is a trademark of Ranbaxy Laboratories Limited
Lidose is a registered trademark of SMB Laboratories.
Accutane is a registered trademark of Hoffman-La Roche
CONTACTS:
Charles M. Caprariello
Robert Ferris
Vice President, Corporate Communications
RF Binder Partners Inc.
Ranbaxy Inc.
(212) 994-7505
(609) 720-5615
http://www.cipherpharma.com/files/DND%20-%20Q4%202012%20Report_v001_s9py6c.pdf
Recent CPH News
- Cipher Pharmaceuticals Reports First Quarter 2024 Results • PR Newswire (Canada) • 05/09/2024 09:00:00 PM
- Cipher Pharmaceuticals Schedules Q1 2024 Earnings Release and Conference Call • PR Newswire (Canada) • 05/03/2024 11:05:00 AM
- Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results • PR Newswire (Canada) • 03/14/2024 09:00:00 PM
- Cipher Pharmaceuticals Schedules Q4 2023 Earnings Release and Conference Call • PR Newswire (Canada) • 03/08/2024 12:00:00 PM
- Will Uplisting Be the Catalyst to Send Sharesof this Pharma Company Higher? • AllPennyStocks.com • 01/29/2024 05:56:00 PM
- Will Uplisting Be the Catalyst to Send Shares of this Pharma Company Higher? • AllPennyStocks.com • 01/29/2024 05:56:00 PM
- Cipher Pharmaceuticals Announces the Commencement of OTCQX Trading • PR Newswire (Canada) • 01/29/2024 12:15:00 PM
- Cipher Pharmaceuticals Announces Change of Auditor • PR Newswire (Canada) • 11/24/2023 10:00:00 PM
- Cipher Pharmaceuticals Announces Normal Course Issuer Bid • PR Newswire (Canada) • 11/15/2023 10:00:00 PM
- Cipher Pharmaceuticals Reports Strong Sales & Earnings Growth in Q3 2023 • PR Newswire (Canada) • 11/09/2023 10:00:00 PM
- Cipher Pharmaceuticals Schedules Q3 2023 Earnings Release and Conference Call • PR Newswire (Canada) • 10/27/2023 11:00:00 AM
- Cipher Pharmaceuticals Announces Final Results of Substantial Issuer Bid • PR Newswire (Canada) • 10/12/2023 01:57:00 PM
- Cipher Pharmaceuticals Provides Reminder of the Upcoming Expiration of its Substantial Issuer Bid • PR Newswire (Canada) • 10/03/2023 11:00:00 AM
- Cipher Pharmaceuticals Announces Intention to Commence Substantial Issuer Bid, Aggregate Price up to $6 Million Canadian Dollars • PR Newswire (Canada) • 09/05/2023 11:00:00 AM
- Cipher Pharmaceuticals Releases Q2 2023 Results, Announces Launch of Epuris in Mexico • PR Newswire (Canada) • 08/10/2023 09:00:00 PM
- Cipher Pharmaceuticals Schedules Q2 2023 Earnings Release and Conference Call • PR Newswire (Canada) • 07/28/2023 11:00:00 AM
- Cipher Partner, Moberg Pharma Announces Approval for MOB-015 in the European Union • PR Newswire (Canada) • 07/05/2023 11:00:00 AM
- Cipher Pharmaceuticals Announces Results of Annual and Special Meeting of Shareholders • PR Newswire (Canada) • 06/21/2023 04:53:00 PM
FEATURED POET Announces Design Win and Collaboration with Foxconn Interconnect Technology for High-speed AI Systems • May 14, 2024 10:09 AM
FEATURED Element79 Gold Corp Reports Exceptionally High-Grade Results from Lucero • May 14, 2024 7:00 AM
VAYK Added New Manager for Expansion into $64 Billion Domestic Short-term Rental Market • VAYK • May 14, 2024 9:00 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM